- Premium Stock Alerts
- Posts
- The Pre-Market Advantage: Get a Head Start on Your Trading Day
The Pre-Market Advantage: Get a Head Start on Your Trading Day
Noor Saba
April 09, 2024
Don’t want emails from us anymore? Click here to unsubscribe
Hello Part-time Trader…👋
Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:
Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.
Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.
Top Pre-Market Movers: Identify early winners poised for a strong market opening.
Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.
FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.
Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.
Sponsored
Elon's Secret "A.I. 2.0" Project
Luke Lango, the man who picked Tesla before it sky-rocketed 1,000%+, has traveled all the way to the Tesla Gigafactory in Texas to reveal Elon's hidden A.I. project.
It's known as "A.I. 2.0", and even though it's not yet known, or available to the general public, Luke Lango has found a "backdoor" method to claim a stake before it goes mainstream.
Click here now to discover how to claim a stake in Elon's "A.I. 2.0" project
Happening Today
✓ 08:55 AM ET – Redbook (YoY)
✓ 10:00 AM ET – IBD/TIPP Economic Optimism
✓ 12:00 PM ET – EIA Short-Term Energy Outlook
✓ 01:00 PM ET – 3-Year Note Auction
PREMARKET SNAPSHOT 📈
Dow Jones holds nearly steady as Stock Futures show a mixed bag with NASDAQ experiencing the largest pre-market decline of 0.045%.
S&P500$5202.39 ⬇️ -0.037% | Dow$38892.8 ⬇️ -0.028% | NASDAQ$18100.191 ⬇️ -0.045% |
SECTOR SNAPSHOT ✨
Today's market sees mixed performance with Real Estate (+0.82%) leading the gainers and Energy (-0.63%) taking the biggest hit.
NAME | PRICE | %CHANGE |
|---|---|---|
Consumer Discretionary | 1,468.41 | +0.75 🟢 |
Consumer Staples | 791.04 | -0.18 🔴 |
Energy | 744.69 | -0.63 🔴 |
Financials | 693.99 | +0.39 🟢 |
Health Care | 1,664.63 | -0.38 🔴 |
Industrials | 1,061.84 | -0.21 🔴 |
Materials | 584.53 | +0.03 🟢 |
Real Estate | 242.82 | +0.82 🟢 |
Information Technology | 3,770.94 | -0.32 🔴 |
Communication Services | 291.23 | -0.02 🔴 |
Utilities | 333.14 | +0.64 🟢 |
Sponsored
MarketBeat Alert: Strong sell signal just issued for these 20 stocks
Our proprietary research has uncovered a serious red flag for these 20 stocks. Each one has been given a rare SELL signal or downgrade from multiple Wall Street firms. And you'll be shocked at some of the big-name stocks on the list.
Go here now to get free instant access to all 20 stocks to sell.
Unusual Volume
📈 Auddia Inc (AUUD) jumped 147.55% to $3.54 on a whopping 159.84 million shares traded after it announced that the U.S. Patent and Trademark Office (USPTO) awarded Auddia with U.S. Patent 11,935,520 for the core AI technology Auddia uses in its flagship faidr app to deliver ad-free AM/FM radio stations to paid subscribers.
📈 Investors went wild, sending Beneficient (BENF) stock soaring 61.17% to $0.08 on a massive volume of 141.5 million shares.
📈 Abnormal activity shook Selina Hospitality PLC. (SLNA), pushing it down -27.40% to $0.04 on a whopping 104.77 million shares traded.
📈 Faraday Future Intelligent Electric Inc (FFIE) stock recently closed 14.80% upper at $0.09 on substantial volume of 52.18 million shares.
📈 Longeveron Inc (LGVN) decrease by -2.27% in a single trading session, with abnormally high trading volume of 50.26 million shares after the company declared the pricing of $5.25 million public offering.
Sponsored
Will Crypto Make People Rich Again Starting April 2024?
One catalyst has kicked off every one of the three major crypto bull markets.
Now, the same catalyst is set to hit again in April 2024.
Details on how to profit here.
Premarket Movers
MyMD Pharmaceuticals, Inc. (MYMD) experiences a substantial 38.52% surge in pre-market trading after filing 8-K form with the SEC.
Rail Vision Ltd. (RVSN) sees a significant 16.56% increase, reaching a pre-market price of $1.83 after announcing its latest achievement: securing an order for its innovative AI-powered Switch Yard System from a Class 1 freight rail company in North America.
Inspire Veterinary Partners, Inc. (IVP) demonstrates a noteworthy 10.11% surge, with a pre-market price of $0.05 after releasing Full Year 2023 financial results.
Pre Market Gainers | Pre Market Change | Pre Market Volume |
|---|---|---|
IVP | +10.11% | 2.77M |
MYMD | +38.52% | 2.51M |
RVSN | +16.56% | 1.72M |
MDIA | +11.92% | 1.31M |
ANGH | +15.18% | 828.16K |
ACRV | +50.59% | 380.01K |
CERO | +5.24% | 119.31K |
GDHG | +6.71% | 64.68K |
BRSH | +2.80% | 61.54K |
LIFW | +6.41% | 55.24K |
Sponsored
Titanium Spotlight: Industry Titan Stops Buying From Russia
The world's largest aerospace company is now boycotting Russian titanium. Despite having enough titanium on hand for now, this titan of industry admits it must start taking steps to ensure long-term continuity.
Could this one company help fulfill the supply shortage?
Important FDA
Recently Announced
April 5, 2024 — AbbVie (ABBV) celebrates a significant milestone with the FDA's decision to grant full approval to ELAHERE for certain ovarian cancer patients on March 22, 2024. This marks a pivotal moment as the FDA converts the accelerated approval of ELAHERE in platinum-resistant ovarian cancer to full approval, offering renewed hope and expanded treatment options for patients.
April 5, 2024 — Bristol-Myers Squibb Co. (BMY) achieves a breakthrough in cancer treatment with the FDA's approval of Opdivo in combination with cisplatin-based chemotherapy as a frontline therapy for adult patients with unresectable or metastatic urothelial carcinoma on March 7, 2024.
Supernus Pharmaceuticals, Inc. (SUPN) faces a setback as the FDA issues a Complete Response Letter for SPN-830, intended for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease, on April 8, 2024. While this presents a hurdle in the development process, Supernus remains dedicated to addressing the unmet needs of Parkinson's patients and advancing novel therapies to enhance their quality of life.
Upcoming Announcements
On April 23, 2024, ImmunityBio, Inc. (IBRX) is eagerly anticipating the FDA's decision regarding N-803 plus BCG for high-risk non-muscle-invasive bladder cancer, holding out hope for a breakthrough in treatment.
April 28, 2024, is a pivotal date for Aquestive Therapeutics Inc. (AQST) as they await the FDA's ruling on Libervant, which could offer significant relief for pediatric epilepsy if given the green light.
As April 30, 2024, draws near, Neurocrine Biosciences Inc. (NBIX) finds itself on the cusp of advancement, eagerly awaiting FDA approval for INGREZZA oral granules, potentially transforming the landscape of tardive dyskinesia treatment.
Happy investing,
Maeve Grace
Editor In Cheif
Premium Trade Alerts
Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.
Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.
Reply